entertainment -WSS

entertainment

author：entertainment 2025-09-02 05:55:18 - browse：4631

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Intellia reports positive results for its CRISPR

WSS

Grail spinoff by Illumina should end disastrous merger attempt

See how much Covid

What STAT readers think about the FDA and patient advocacy

In Spain, a hospital brews its own CAR

Cord blood banking comes at a high cost to babies

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

leisure time

entertainment

knowledge

Psychedelics group wrestles with new pharma identity

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Peter Hotez and the public health issue of online harassment

How to increase colonoscopy rates? Looks like an AI can help

State Dept. review finds Biden bears some blame for Afghanistan failures

Ionis drug prevents swelling attacks due to hereditary angioedema

At least 13 dead in Texas as scorching temps continue

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Malaria cases in Florida and Texas: Here’s what you need to know

Why health care costs have stayed mostly flat since 2010

leisure time

Carvykti CAR

Prime Medicine, Myeloid Therapeutics clash over genome

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Shifting the focus from loneliness to social health

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Intellia reports positive results for its CRISPR

hotspot

focus

knowledge

knowledge